Paradigm Biopharmaceuticals Ltd (ASX: PAR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Paradigm Biopharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$114.21 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
439.25 million
Earnings per share
-0.099
Dividend per share
N/A
Year To Date Return
-26.47%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Paradigm Biopharmaceuticals Ltd (ASX: PAR)
Latest News
Share Gainers
Why Appen, Core Lithium, Paradigm, and Sayona Mining shares are racing higher
Share Fallers
Why Best & Less, Cettire, Life360, and Paradigm shares are sinking today
Healthcare Shares
Why is this ASX All Ords biotech share crashing 12% today?
Share Market News
Why Appen, GQG, Paradigm, and Talga shares are tumbling lower
Share Gainers
Boom! Guess which ASX All Ords share has surged 50% this week
Share Gainers
Why Allkem, Evolution, Paradigm, and Sayona Mining shares are zooming higher
Healthcare Shares
Why is the Paradigm share price rocketing 19% today?
Share Gainers
3 ASX All Ords shares that marched higher on Friday
Share Fallers
Why Beach, Bendigo and Adelaide Bank, Opthea, and Paradigm shares are sinking
Capital Raising
Paradigm Biopharmaceuticals share price freefalls 27% following $66m cap raise
Capital Raising
Up 90% in 2 weeks, here's why the Paradigm share price has been halted
Share Gainers
Why Appen, Imugene, OZ Minerals, and Paradigm shares are charging higher
PAR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Paradigm Biopharmaceuticals Ltd
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
PAR Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 13 Mar 2026 | $0.26 | $0.01 | 4.00% | 894,342 | $0.25 | $0.27 | $0.25 |
| 12 Mar 2026 | $0.25 | $-0.01 | -3.85% | 736,940 | $0.25 | $0.26 | $0.25 |
| 11 Mar 2026 | $0.26 | $0.00 | 0.00% | 585,331 | $0.26 | $0.26 | $0.25 |
| 10 Mar 2026 | $0.26 | $0.01 | 4.00% | 781,726 | $0.27 | $0.27 | $0.25 |
| 09 Mar 2026 | $0.25 | $-0.01 | -3.92% | 506,615 | $0.26 | $0.26 | $0.24 |
| 06 Mar 2026 | $0.26 | $0.00 | 0.00% | 355,045 | $0.25 | $0.26 | $0.25 |
| 05 Mar 2026 | $0.26 | $0.01 | 4.00% | 1,210,228 | $0.26 | $0.26 | $0.25 |
| 04 Mar 2026 | $0.25 | $0.00 | 0.00% | 1,736,573 | $0.25 | $0.25 | $0.24 |
| 03 Mar 2026 | $0.25 | $-0.01 | -3.92% | 1,576,459 | $0.26 | $0.26 | $0.25 |
| 02 Mar 2026 | $0.26 | $-0.01 | -3.85% | 1,274,670 | $0.26 | $0.27 | $0.26 |
| 27 Feb 2026 | $0.26 | $-0.01 | -3.70% | 1,628,717 | $0.27 | $0.27 | $0.26 |
| 26 Feb 2026 | $0.27 | $-0.01 | -3.64% | 1,134,493 | $0.28 | $0.29 | $0.27 |
| 25 Feb 2026 | $0.28 | $0.01 | 3.70% | 924,511 | $0.27 | $0.28 | $0.26 |
| 24 Feb 2026 | $0.27 | $-0.01 | -3.64% | 858,390 | $0.28 | $0.28 | $0.27 |
| 23 Feb 2026 | $0.28 | $-0.01 | -3.57% | 538,030 | $0.29 | $0.29 | $0.28 |
| 20 Feb 2026 | $0.28 | $-0.01 | -3.45% | 916,698 | $0.30 | $0.30 | $0.28 |
| 19 Feb 2026 | $0.29 | $0.00 | 0.00% | 698,316 | $0.30 | $0.30 | $0.29 |
| 18 Feb 2026 | $0.29 | $-0.01 | -3.39% | 1,489,942 | $0.29 | $0.30 | $0.29 |
| 17 Feb 2026 | $0.30 | $-0.01 | -3.28% | 1,084,950 | $0.31 | $0.31 | $0.30 |
| 16 Feb 2026 | $0.31 | $0.01 | 3.33% | 593,155 | $0.30 | $0.31 | $0.30 |
| 13 Feb 2026 | $0.30 | $-0.01 | -3.28% | 505,628 | $0.31 | $0.31 | $0.30 |
| 12 Feb 2026 | $0.31 | $-0.01 | -3.23% | 736,127 | $0.31 | $0.31 | $0.31 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 19 Feb 2026 | Paul Rennie | Issued | 76,633 | $22,223 |
Issue of options.
|
| 18 Feb 2026 | Matthew Fry | Expiry | 354,958 | $102,937 |
Options expired.
|
| 18 Feb 2026 | Paul Rennie | Expiry | 5,028,423 | $1,458,242 |
Options expired.
|
| 17 Feb 2026 | Paul Rennie | Issued | 1,500,000 | $442,500 |
Issue of securities. 3,200,000 rights
|
| 03 Feb 2026 | Paul Rennie | Exercise | 153,265 | $48,278 |
Exercise of options.
|
| 03 Feb 2026 | Paul Rennie | Buy | 153,265 | $99,622 |
Exercise of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Paul Rennie | Executive DirectorManaging DirectorExecutive Chairman | May 2014 |
Mr Rennie has sales, marketing, business development, operational and IP commercialization experience in the biopharmaceutical sector. Paul's experience includes working for Boehringer Mannheim (now Roche Diagnostics), Merck KGGA as national sales and marketing manager and Soltec (FH Faulding Ltd) as their director of business development. Paul also led the commercialization of Recaldent a novel biopharmaceutical arising from research at the dental school, University of Melbourne. Paul took an R&D project from the laboratory bench to a commercial product now marketed globally as an additive to oral care products. More recently Paul worked in several positions with Mesoblast Ltd. Paul was the inaugural COO and moved into Executive Vice President New Product Development for the adult stem cell company. Paul is the founder of Paradigm Biopharmaceuticals.
|
| Mr Amos Meltzer | Non-Executive Director | Dec 2020 |
Mr Meltzer has over 30 years of experience in international trade and in commercializing technologies, principally in the life sciences sector. He has presided over life science research and product development projects clinical trials as well as the commercialization of life sciences assets through both licensing and the sale and marketing of a pharmaceutical product. Previously Amos served as General Counsel and IP director at two Nasdaq-listed companies Compugen and Gilat, as a non-executive director of a biotechnology company Evogene and as VP of Business Development. Amos currently serves as Chief Legal Officer of neuro-medical device company Synchron, Inc., chairman of the Board of Maverick LifeSciences.
|
| Mr Matthew James Fry | Non-Executive Director | Mar 2024 |
Mr Fry has more than 25 years in business creation, strategy, and expansion in healthcare and medical diagnostics globally. He is currently the CEO, Managing Director and Founder of AM Diagnostics Pty Ltd, a manufacturer and distributor of medical diagnostic products. Matthew has experience with global regulatory agencies, in particular the Australian TGA and US FDA.
|
| Ms Abby Macnish | Interim Company Secretary | Aug 2022 |
-
|
| Abby Macnish | Interim Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 20,216,245 | 5.09% |
| HSBC Custody Nominees (Australia) Limited | 14,090,211 | 3.55% |
| Kzee Pty Ltd <Kzee Superannuation Fund A/C> | 11,380,902 | 2.86% |
| Mr Evan Philip Clucas & Ms Leanne Jane Weston <Kuranga Nursery Super A/C> | 9,768,128 | 2.46% |
| Mr Paul John Rennie | 8,745,848 | 2.20% |
| BNP Paribas Nominees Pty Ltd <IB Au Noms Retailclient> | 8,535,566 | 2.15% |
| Mr Anthony Mark Van Der Steeg | 4,649,524 | 1.17% |
| Mr Adam William Huts | 3,680,000 | 0.93% |
| Nancy Edith Wilson Ghosh <Ghosh Family A/C> | 3,475,835 | 0.87% |
| BNP Paribas Noms Pty Ltd | 2,874,158 | 0.72% |
| Flinders Medical Centre Foundation | 2,620,000 | 0.66% |
| 39Kp Pty Ltd <Ross Family A/C> | 2,527,367 | 0.64% |
| Mrs Shay Elizabeth Lewis Thorp | 2,500,000 | 0.63% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 2,201,776 | 0.55% |
| Obsidian Global Gp Llc | 2,031,235 | 0.51% |
| J P Morgan Nominees Australia Pty Limited | 2,005,079 | 0.50% |
| Ms Yanicke Forfang | 1,950,000 | 0.49% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 1,838,801 | 0.46% |
| Hot Springs Superannuation Pty Limited <Hot Springs Limited S/F A/C> | 1,752,090 | 0.44% |
| Mr Ignatius John Misquitta & Mrs Margaret Misquitta | 1,650,000 | 0.42% |